Modeling Adult Gliomas Using RCAS/t-va Technology.

Malignant gliomas remain the most devastating childhood and adult tumors of the central nervous system. Although adult and pediatric gliomas are histologically indistinguishable, they differ in location, behavior, and molecular characteristics. This implies that the molecular pathways and pathophysiology of malignant gliomagenesis in these two populations are distinct. Such differences between adult and pediatric gliomas may predict different therapeutic responses. Therefore, accurate genetically engineered models of adult and pediatric gliomas may help understand the biology of these tumors and evaluate therapeutic agents in preclinical studies. It has been proposed that gliomas arise from the subventricular zone in mice during development. Here, we demonstrate that, in adult mice, gliomas may arise not only when injected in the subventricular zone but also when injected in the cortex and cerebellum. Our work demonstrates a versatile and highly reproducible adult mouse model of glioma, which can be easily incorporated into preclinical studies.

[1]  C. Cordon-Cardo,et al.  Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas. , 2008, Cancer research.

[2]  Anssi Auvinen,et al.  Incidence of gliomas by anatomic location. , 2007, Neuro-oncology.

[3]  R. Gilbertson,et al.  Tumorigenesis in the brain: location, location, location. , 2007, Cancer research.

[4]  Arie Perry,et al.  Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. , 2007, Cancer research.

[5]  C. James,et al.  Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. , 2006, Journal of neurosurgery.

[6]  Eric C. Holland,et al.  Mouse Models of Brain Tumors and Their Applications in Preclinical Trials , 2006, Clinical Cancer Research.

[7]  Yuri Kotliarov,et al.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. , 2006, Cancer cell.

[8]  E. Holland,et al.  Genetically engineered models have advantages over xenografts for preclinical studies. , 2006, Cancer research.

[9]  E. Holland,et al.  Platelet-derived growth factor (PDGF) and glial tumorigenesis. , 2006, Cancer letters.

[10]  T. MacDonald,et al.  Pediatric High-grade Glioma: Molecular Genetic Clues for Innovative Therapeutic Approaches , 2005, Journal of Neuro-Oncology.

[11]  J. Laterra,et al.  Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. , 2005, Neuro-oncology.

[12]  Amar Gajjar,et al.  Radial glia cells are candidate stem cells of ependymoma. , 2005, Cancer cell.

[13]  T. Hakan,et al.  Primary cerebellar glioblastoma multiforme. , 2005, Diagnostic and interventional radiology.

[14]  P. Pandolfi,et al.  mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. , 2005, Neoplasia.

[15]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[16]  J. Bleby,et al.  Laboratory animal medicine. , 2003, The Veterinary record.

[17]  P. Pandolfi,et al.  Pten Dose Dictates Cancer Progression in the Prostate , 2003, PLoS biology.

[18]  E. Holland,et al.  Using mice to decipher the molecular genetics of brain tumors. , 2003, Neurosurgery.

[19]  Paul S Mischel,et al.  Gene expression profiling identifies molecular subtypes of gliomas , 2003, Oncogene.

[20]  Daniel J Brat,et al.  Genetic Markers in Glioblastoma: Prognostic Significance and Future Therapeutic Implications: On: Impact of Genotype Morphology on the Prognosis of Glioblastoma. Schmidt MC Antweiler S, Urban N, et al. J Neuropathol Exp Neurol 2002;61:321–328. , 2003, Advances in anatomic pathology.

[21]  Paul S Mischel,et al.  Identification of molecular subtypes of glioblastoma by gene expression profiling , 2003, Oncogene.

[22]  J. Wellons,et al.  Pediatric High‐Grade Gliomas , 2003, Cancer journal.

[23]  G. Fuller,et al.  Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. , 2002, Cancer research.

[24]  K. Makino,et al.  Influence of p53 mutations on prognosis of patients with glioblastoma , 2002, Cancer.

[25]  A. Álvarez-Buylla,et al.  Identification of neural stem cells in the adult vertebrate brain , 2002, Brain Research Bulletin.

[26]  G. Fuller,et al.  Genetic Modeling of Glioma Formation in Mice , 2002, Brain pathology.

[27]  J J Mazeron,et al.  Brainstem gliomas in adults: prognostic factors and classification. , 2001, Brain : a journal of neurology.

[28]  D. Louis,et al.  PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. , 2001, Genes & development.

[29]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[30]  E. Holland,et al.  Modeling Gliomagenesis with Somatic Cell Gene Transfer using Retroviral Vectors , 2001, Journal of Neuro-Oncology.

[31]  Eric C. Holland,et al.  Gliomagenesis: genetic alterations and mouse models , 2001, Nature Reviews Genetics.

[32]  M. Prados,et al.  Biology and treatment of malignant glioma. , 2000, Seminars in oncology.

[33]  R. Carroll,et al.  Platelet-derived growth factor and its receptor expression in human oligodendrogliomas. , 1998, Neurosurgery.

[34]  G. Reifenberger,et al.  CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. , 1994, Cancer research.

[35]  J. Bruner,et al.  Fibroblast growth factor receptor gene expression and immunoreactivity are elevated in human glioblastoma multiforme. , 1994, Cancer research.

[36]  J. Bruner,et al.  Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[37]  C. Heldin,et al.  Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. , 1992, Cancer research.

[38]  C. James,et al.  Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. , 1991, Cancer research.

[39]  J. Cairncross,et al.  Selection bias in clinical trails of anaplastic glioma , 1989, Annals of neurology.

[40]  T. Libermann,et al.  Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines. , 1988, Cancer research.

[41]  Hermona Soreq,et al.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin , 1985, Nature.

[42]  J. Schaper,et al.  Cholesteatoma of the middle ear in human patients. An ultrastructural study. , 1976, Archives of otolaryngology.

[43]  H. Armah.  Malignant Astrocytomas Originate from Neural Stem/Progenitor Cells in a Somatic Tumor Suppressor Mouse Model , 2010 .

[44]  Yuta Shibamoto,et al.  Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach , 2005, Journal of Neuro-Oncology.

[45]  S. Züchner,et al.  CNTF and its Receptor Subunits in Human Gliomas , 2004, Journal of Neuro-Oncology.

[46]  J. Koutcher,et al.  MRI of mouse models for gliomas shows similarities to humans and can be used to identify mice for preclinical trials. , 2002, Neoplasia.

[47]  D. Louis,et al.  CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. , 1996, Cancer research.

[48]  D. Nelson,et al.  Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. , 1993, International journal of radiation oncology, biology, physics.